[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604090":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":37,"locations":10,"responsibleParty":42,"collaborators":10,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":10,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":10,"overallStatus":63,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":10},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Fruquintinib + paclitaxel",null,"Group 1: Fruquintinib + Paclitaxel (IPD)",[13],"Drug: Fruquintinib+Paclitaxel",{"label":15,"type":10,"description":16,"interventionNames":17},"Ramucirumab + paclitaxel","Group 2: Control Therapy (AgD from RAINBOW-Asia)",[18],"Drug: Ramucirumab+Paclitaxel",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Fruquintinib+Paclitaxel","(using IPD from the FRUTIGA trial, n=703) Fruquintinib：subjects received Fruquintinib orally, once daily for 3 wks on\u002F 1 wk off Paclitaxel：Paclitaxel 80mg\u002F㎡ at day 1,8,15 of 4-week cycle.",[9],[26],"HMPL-013+paclitaxel",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Ramucirumab+Paclitaxel","(using published AgD from RAINBOW-Asia, n=440) Ramucirumab：8 milligrams\u002Fkilogram (mg\u002Fkg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle Paclitaxel ：Paclitaxel 80mg\u002F㎡ at day 1,8,15 of 4-week cycle.",[15],[32],"LY3009806 +paclitaxel",[34],{"name":35,"affiliation":5,"role":36},"Feng Wang","PRINCIPAL_INVESTIGATOR",[38],{"name":35,"role":39,"phone":40,"phoneExt":10,"email":41},"CONTACT","020-8734-3571","wangfeng@sysucc.org.cn",{"type":36,"investigatorFullName":35,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Professor","100604090","maic-of-fruquintinib-plus-paclitaxel-versus-ramucirumab-plus-paclitaxel-in-advanced-ggej-adenocarcinoma-100604090",false,"NCT07144995","MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G\u002FGEJ Adenocarcinoma","Adjusted Indirect Treatment Comparison of Fruquintinib-based Therapy Versus Standard Care in Advanced Gastric\u002FGastroesophageal Junction Adenocarcinoma: A MAIC Analysis.","Inclusion Criteria:\n\n* Histologically confirmed gastric\u002FGEJ adenocarcinoma\n* Advanced or metastatic disease\n* ECOG 0-1\n* Received either fruquintinib + paclitaxel or reference regimen\n* Available baseline characteristics for matching variables\n\nExclusion Criteria:\n\n* Missing key outcome data\n* Incomplete baseline characteristics for \\>2 matching variables\n* Prior fruquintinib exposure (control arm only)","ALL","18 Years",{"count":54,"type":55},1143,"ESTIMATED","OBSERVATIONAL","This anchored matching-adjusted indirect comparison (MAIC) evaluates the relative efficacy of fruquintinib-paclitaxel (using IPD from the FRUTIGA trial, n=703) versus ramucirumab-paclitaxel (using published AgD from RAINBOW-Asia, n=440) in advanced gastric\u002FGEJ adenocarcinoma. Baseline characteristics are adjusted via entropy balancing weights. Primary endpoint is progression-free survival (PFS) analyzed by Bucher method; secondary endpoints include overall survival (OS) and objective response rate (ORR). Sensitivity analyses comprise restricted mean survival time (RMST) analysis and simulated treatment comparison (STC).",[59,60,61,62],"Advanced Gastric Cancer","Gastroesophageal Junction Adenocarcinoma","Fruquintinib","Ramucirumab","NOT_YET_RECRUITING","2025-08-20",{"date":66,"type":67},"2025-08-28","ACTUAL",{"date":69,"type":55},"2025-09-05",{"date":71,"type":55},"2026-12-31",{"name":5,"class":6}]